{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:37:18Z","timestamp":1793137038130,"version":"4.5.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,28]]},"abstract":"<jats:p>Prostate cancer is a leading malignancy worldwide, and while radical prostatectomy is an effective treatment for localized disease, a significant proportion of patients experience biochemical recurrence. Prostate-specific antigen (PSA) remains the primary biomarker for recurrence detection, but its limitations in specificity necessitate improved surveillance tools. Liquid biopsy techniques, particularly exosomal microRNAs (miRNAs) and circulating tumor DNA (ctDNA), have emerged as promising noninvasive biomarkers for early recurrence detection. However, their comparative diagnostic accuracy remains unclear. This narrative review explores the diagnostic potential of exosomal miRNAs and ctDNA for early recurrence detection following radical prostatectomy. It examines their biological characteristics, detection methodologies, comparative diagnostic performance, and clinical challenges. Both exosomal miRNAs and ctDNA hold significant potential for the early detection of prostate cancer recurrence post-radical prostatectomy. However, the lack of standardized protocols and the variability in current studies limit definitive conclusions about their relative accuracy. Future large-scale, prospective studies are necessary to validate their clinical utility and establish guidelines for their integration into routine surveillance. A multi-biomarker approach combining exosomal miRNAs, ctDNA, and PSA may provide the most effective strategy for personalized prostate cancer monitoring.<\/jats:p>","DOI":"10.1097\/md.0000000000046239","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:02:01Z","timestamp":1764597721000},"page":"e46239","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Exosomal miRNAs versus circulating tumor DNA: diagnostic accuracy for early detection of recurrence post-radical prostatectomy: A narrative review"],"prefix":"10.1097","volume":"104","author":[{"given":"Hamza","family":"Bashir","sequence":"first","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Waqas","family":"Afzal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Mehmood","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maham","family":"Afzal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Wasi","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3310-5442","authenticated-orcid":false,"given":"Abida","family":"Parveen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260121","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer.","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"R2-20260121","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","article-title":"Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.","volume":"27","author":"Shore","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R3-20260121","doi-asserted-by":"crossref","first-page":"127rv","DOI":"10.1126\/scitranslmed.3003180","article-title":"Beyond PSA: the next generation of prostate cancer biomarkers.","volume":"4","author":"Prensner","year":"2012","journal-title":"Sci Transl Med"},{"key":"R4-20260121","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-022-01525-9","article-title":"Liquid biopsy: exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer.","volume":"21","author":"Preethi","year":"2022","journal-title":"Mol Cancer"},{"key":"R5-20260121","doi-asserted-by":"crossref","first-page":"15330338231205999","DOI":"10.1177\/15330338231205999","article-title":"The emerging role of exosomal miRNAs as biomarkers for early cancer detection: a comprehensive literature review.","volume":"22","author":"Jafari","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"R6-20260121","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.3390\/cancers14246025","article-title":"Circulating tumor DNA-A novel biomarker of tumor progression and its favorable detection techniques.","volume":"14","author":"Wen","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R7-20260121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4111\/icu.20200395","article-title":"Clinical utility of current biomarkers for prostate cancer detection.","volume":"62","author":"Kim","year":"2021","journal-title":"Investig Clin Urol"},{"key":"R8-20260121","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.3390\/cancers12082009","article-title":"MicroRNAs from liquid biopsy derived extracellular vesicles: recent advances in detection and characterization methods.","volume":"12","author":"Drula","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R9-20260121","doi-asserted-by":"crossref","first-page":"FSO72","DOI":"10.4155\/fso.15.72","article-title":"Biomarkers for prostate cancer: present challenges and future opportunities.","volume":"2","author":"Sharma","year":"2015","journal-title":"Future Sci OA"},{"key":"R10-20260121","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12967-021-03215-4","article-title":"The role of Exosomal miRNAs in cancer.","volume":"20","author":"Li","year":"2022","journal-title":"J Transl Med"},{"key":"R11-20260121","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1002\/mco2.766","article-title":"Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges.","volume":"5","author":"Li","year":"2024","journal-title":"MedComm (2020)"},{"key":"R12-20260121","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1002\/sim.10230","article-title":"Combining biomarkers to improve diagnostic accuracy in detecting diseases with group-tested data.","volume":"43","author":"Yang","year":"2024","journal-title":"Stat Med"},{"key":"R13-20260121","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation.","volume":"9","author":"O\u2019Brien","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R14-20260121","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1007\/s11255-018-1938-2","article-title":"Combination of three miRNA (miR-141, miR-21, and miR-375) as potential diagnostic tool for prostate cancer recognition.","volume":"50","author":"Porzycki","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"R15-20260121","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-022-01710-w","article-title":"Circulating tumor nucleic acids: biology, release mechanisms, and clinical relevance.","volume":"22","author":"Stejskal","year":"2023","journal-title":"Mol Cancer"},{"key":"R16-20260121","doi-asserted-by":"crossref","first-page":"48832","DOI":"10.18632\/oncotarget.9453","article-title":"Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.","volume":"7","author":"Cheng","year":"2016","journal-title":"Oncotarget"},{"key":"R17-20260121","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41416-020-01047-5","article-title":"Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond.","volume":"124","author":"Keller","year":"2021","journal-title":"Br J Cancer"},{"key":"R18-20260121","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/ijc.34813","article-title":"Analysis of immune-related adverse events in gastrointestinal malignancy patients treated with immune checkpoint inhibitors.","volume":"154","author":"Niu","year":"2024","journal-title":"Int J Cancer"},{"key":"R19-20260121","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/medicina56020094","article-title":"MiRNA-based inspired approach in diagnosis of prostate cancer.","volume":"56","author":"Munteanu","year":"2020","journal-title":"Medicina (Kaunas)"},{"key":"R20-20260121","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1158\/0008-5472.CAN-17-2069","article-title":"microRNA-1246 is an exosomal biomarker for aggressive prostate cancer.","volume":"78","author":"Bhagirath","year":"2018","journal-title":"Cancer Res"},{"key":"R21-20260121","doi-asserted-by":"crossref","first-page":"943253","DOI":"10.3389\/fonc.2022.943253","article-title":"Circulating Tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis.","volume":"12","author":"S\u00e1nchez-Herrero","year":"2022","journal-title":"Front Oncol"},{"key":"R22-20260121","doi-asserted-by":"crossref","first-page":"532","DOI":"10.3390\/cancers14030532","article-title":"Exploration of extracellular vesicle miRNAs, targeted mRNAs and pathways in prostate cancer: relation to disease status and progression.","volume":"14","author":"Puhka","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R23-20260121","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/cas.16097","article-title":"Beyond blood: Advancing the frontiers of liquid biopsy in oncology and personalized medicine.","volume":"115","author":"Bao","year":"2024","journal-title":"Cancer Sci"},{"key":"R24-20260121","first-page":"127","article-title":"Artificial intelligence in cancer imaging: clinical challenges and applications.","volume":"69","author":"Bi","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R25-20260121","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12967-024-05067-0","article-title":"Tribulations and future opportunities for artificial intelligence in precision medicine.","volume":"22","author":"Carini","year":"2024","journal-title":"J Transl Med"},{"key":"R26-20260121","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.3390\/ijms25063403","article-title":"The circulating biomarkers league: combining miRNAs with cell-free DNAs and proteins.","volume":"25","author":"Felekkis","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R27-20260121","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-3-319-93339-9_4","article-title":"Liquid biopsy in prostate cancer: circulating tumor cells and beyond.","volume":"175","author":"Zainfeld","year":"2018","journal-title":"Cancer Treat Res"},{"key":"R28-20260121","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/cancers16010057","article-title":"Exosomal DNA: role in reflecting tumor genetic heterogeneity, diagnosis, and disease monitoring.","volume":"16","author":"Xiang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R29-20260121","doi-asserted-by":"crossref","first-page":"1756287221997186","DOI":"10.1177\/1756287221997186","article-title":"Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management.","volume":"13","author":"Saltman","year":"2021","journal-title":"Ther Adv Urol"},{"key":"R30-20260121","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/cts.12764","article-title":"Clinical trial generalizability assessment in the big data era: a review.","volume":"13","author":"He","year":"2020","journal-title":"Clin Transl Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046239","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T11:03:28Z","timestamp":1768993408000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":30,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046239","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"2025-05-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}